---
title: Characteristics of Patients With Hypersensitivity Reactions to Intravenous Iron Infusions
nct_id: NCT04359368
overall_status: COMPLETED
sponsor: University Hospital, Basel, Switzerland
study_type: OBSERVATIONAL
primary_condition: Iron-deficiency
countries: Switzerland
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04359368.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04359368"
ct_last_update_post_date: 2020-04-24
last_seen_at: "2026-05-12T06:51:01.118Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Characteristics of Patients With Hypersensitivity Reactions to Intravenous Iron Infusions

**Official Title:** Characteristics of Patients With Hypersensitivity Reactions to Intravenous Iron Infusions - a Retrospective Study

**NCT ID:** [NCT04359368](https://clinicaltrials.gov/study/NCT04359368)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 42
- **Lead Sponsor:** University Hospital, Basel, Switzerland
- **Conditions:** Iron-deficiency, Hypersensitivity Reactions
- **Start Date:** 2019-09-01
- **Completion Date:** 2019-10-31
- **CT.gov Last Update:** 2020-04-24

## Brief Summary

This study aims to evaluate characteristics of patients with previous hypersensitivity reaction grades I-IV to intravenous ferric carboxymaltose (Ferinject) or to iron sucrose (Venofer) including age, atopy status, previous allergic reactions, previous medical history, current medications and co-morbidities. Furthermore, symptoms on reaction such as severity grade of reaction will be evaluated.

## Eligibility

- **Minimum age:** 16 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Participants from 16 years of age and older with previous hypersensitivity reaction grades I-IV to intravenous ferric carboxymaltose (Ferinject) or to iron sucrose (Venofer).

Exclusion Criteria:

* No previous hypersensitivity reaction to iron preparations or reactions to oral iron preparations.
* If a rejection to use patient data is documented in patient records, the patient will be excluded from analysis.
```

## Arms

- **patients with hypersensitivity reactions to NDIPs** — Patients with previous hypersensitivity reaction grades I-IV to intravenous ferric carboxymaltose (Ferinject) or to iron sucrose (Venofer)

## Interventions

- **collection of patient data** (OTHER) — Data collection (history, clinical presentation, medication, complications, laboratory testing) will be performed from patient records stored in the protected electronic patient system ISMed (Integrated System for Medical Diagnostic) of patients with HSRs to NDIPs.

## Primary Outcomes

- **previous medical history** _(time frame: Baseline; Patients with HSRs to NDIPs that were treated at the University Hospital Basel between the 16th of January 2018 and the 24th of October 2019)_ — Data collection (medical history) will be performed from patient records stored in the protected electronic patient system ISMed (Integrated System for Medical Diagnostic) of patients with HSRs to NDIPs
- **Family history** _(time frame: Baseline; Patients with HSRs to NDIPs that were treated at the University Hospital Basel between the 16th of January 2018 and the 24th of October 2019)_ — Data collection (Family history) will be performed from patient records stored in the protected electronic patient system ISMed (Integrated System for Medical Diagnostic) of patients with HSRs to NDIPs
- **assessment of hypersensitivity reactions** _(time frame: Baseline; Patients with HSRs to NDIPs that were treated at the University Hospital Basel between the 16th of January 2018 and the 24th of October 2019)_ — assessment of hypersensitivity reactions (grade I-IV) to Ferinject or Venofer
- **preparation used** _(time frame: Baseline; Patients with HSRs to NDIPs that were treated at the University Hospital Basel between the 16th of January 2018 and the 24th of October 2019)_ — which preparation was used for Treatment ( iron sucrose (Venofer) or ferric carboxymaltose (Ferinject)
- **co-medication** _(time frame: Baseline; Patients with HSRs to NDIPs that were treated at the University Hospital Basel between the 16th of January 2018 and the 24th of October 2019)_ — which co-medication was used

## Locations (1)

- University Hospital Basel, Basel, Switzerland

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university hospital basel|basel||switzerland` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04359368.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04359368*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*